Can you take Brodalumab with Iophen DM NR?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- brodalumab
- Iophen DM NR (dextromethorphan/guaifenesin)
Drug interactions
Moderate drug interactions
Moderate:
dextromethorphan brodalumab
Applies to: Iophen DM NR (dextromethorphan / guaifenesin) and brodalumab
Brodalumab may alter the blood levels and effects of dextromethorphan. Your doctor may need to monitor you more closely and/or adjust the dosing of your medication(s). For example, a dose adjustment may be needed if you have been receiving dextromethorphan and are starting treatment with brodalumab. Likewise, if you have been receiving both medications, the dose of dextromethorphan may need to be adjusted when brodalumab is discontinued. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
dextromethorphan Food/Lifestyle
Applies to: Iophen DM NR (dextromethorphan / guaifenesin)
Alcohol can increase the nervous system side effects of dextromethorphan such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with dextromethorphan. Do not use more than the recommended dose of dextromethorphan, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.
Disease interactions
6 potential interactions Applies to: 6 conditions, including Depression, Inflammatory Bowel Disease, Infection, Tuberculosis, Active, and Tuberculosis, Latent.
Depression
Major:
brodalumab
Brodalumab has a major potential interaction with Depression.
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with brodalumab. Patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior. Prescribers should weigh the potential risks and benefits before using brodalumab in patients with a history of depression or suicidality. Families and caregivers should be advised of the need for close observation and communication with the treating physician.
Infection
Moderate:
brodalumab
Brodalumab has a moderate potential interaction with Infection.
The use of brodalumab of may increase the risk of infections. When using this agent in patients with a chronic infection or a history of recurrent infection, it is recommended to consider the risks and benefits prior to prescribing brodalumab. Therapy discontinuation may be considered if a patient develops a serious infection or is not responding to standard therapy for the infection. Care should be exercised when prescribing this agent to patients with an existing infection.
Inflammatory Bowel Disease
Major:
brodalumab
Brodalumab has a major potential interaction with Inflammatory Bowel Disease.
The use of brodalumab is contraindicated in patients with Crohn's disease as this agent may cause worsening of the disease. It is recommended to discontinue the use of brodalumab if patients develop Crohn's disease while on treatment.
Tuberculosis, Active
Major:
brodalumab
Brodalumab has a major potential interaction with Tuberculosis, Active.
Brodalumab should not be administered to patients with active tuberculosis infection. It is recommended to evaluate patients for tuberculosis infection prior to initiating treatment with brodalumab and initiate treatment for latent tuberculosis prior to administering this agent. Consider anti- tuberculosis therapy prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. Closely monitor patients receiving brodalumab for signs and symptoms of active tuberculosis during and after treatment.
Tuberculosis, Latent
Major:
brodalumab
Brodalumab has a major potential interaction with Tuberculosis, Latent.
Brodalumab should not be administered to patients with active tuberculosis infection. It is recommended to evaluate patients for tuberculosis infection prior to initiating treatment with brodalumab and initiate treatment for latent tuberculosis prior to administering this agent. Consider anti- tuberculosis therapy prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. Closely monitor patients receiving brodalumab for signs and symptoms of active tuberculosis during and after treatment.
Vaccination
Major:
brodalumab
Brodalumab has a major potential interaction with Vaccination.
The use of live vaccines in patients treated with brodalumab should be avoided. No data are available on the ability of live or inactive vaccines to elicit an immune response in patients being treated with this agent.
Report options
More resources
brodalumab
A total of 314 drugs are known to interact with brodalumab.
- Brodalumab is in the drug class interleukin inhibitors.
- Brodalumab is used to treat the following conditions:
Iophen DM NR
A total of 375 drugs are known to interact with Iophen DM NR.
- Iophen dm nr is in the drug class upper respiratory combinations.
- Iophen dm nr is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.